171 related articles for article (PubMed ID: 38023970)
1. Influence of nonalcoholic fatty liver disease on inflammatory bowel disease hospitalizations in the United States.
Soni A; Yekula A; Dahiya DS; Sundararajan R; Dutta P; Singh Y; Cheng CI; Abraham G
Ann Gastroenterol; 2023; 36(6):646-653. PubMed ID: 38023970
[TBL] [Abstract][Full Text] [Related]
2. The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis.
Noorian S; Jeon Y; Nguyen MT; Sauk J; Limketkai BN
Inflamm Bowel Dis; 2022 Jun; 28(6):878-887. PubMed ID: 34374782
[TBL] [Abstract][Full Text] [Related]
3. A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations.
Dahiya DS; Kichloo A; Wani F; Singh J; Solanki D; Shaka H
Intest Res; 2022 Jul; 20(3):342-349. PubMed ID: 34011019
[TBL] [Abstract][Full Text] [Related]
4. Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States.
Hirode G; Vittinghoff E; Wong RJ
J Clin Gastroenterol; 2019; 53(10):765-771. PubMed ID: 31135632
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.
Reddy SK; Zhan M; Alexander HR; El-Kamary SS
World J Gastroenterol; 2013 Dec; 19(45):8301-11. PubMed ID: 24363521
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States.
Adejumo AC; Samuel GO; Adegbala OM; Adejumo KL; Ojelabi O; Akanbi O; Ogundipe OA; Pani L
Ann Gastroenterol; 2019; 32(5):504-513. PubMed ID: 31474798
[TBL] [Abstract][Full Text] [Related]
7. Peptic ulcer disease in non-alcoholic fatty liver disease hospitalizations: A new challenge on the horizon in the United States.
Dahiya DS; Jahagirdar V; Ali H; Gangwani MK; Aziz M; Chandan S; Singh A; Perisetti A; Soni A; Inamdar S; Sanaka MR; Al-Haddad M
World J Hepatol; 2023 Apr; 15(4):564-576. PubMed ID: 37206652
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.
Abenavoli L; Spagnuolo R; Scarlata GGM; Scarpellini E; Boccuto L; Luzza F
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003983
[No Abstract] [Full Text] [Related]
9. Association of nonalcoholic fatty liver disease with acute cholangitis: a nationwide propensity-matched analysis from the United States.
Patel P; Inayat F; Ali H; Afzal A; Taj S; Rehman AU; Hussain N; Ishtiaq R; Nawaz G; Afzal MS; Fatakhova K; Satapathy SK
Proc (Bayl Univ Med Cent); 2023; 36(5):600-607. PubMed ID: 37614865
[TBL] [Abstract][Full Text] [Related]
10. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Hospital-related Outcomes of COVID-19 Infection in Patients With Inflammatory Bowel Disease in the Early Pandemic Phase: A Nationwide Inpatient Database Survey.
Naseem K; Sohail A; Quang Nguyen V; Khan A; Cooper G; Lashner B; Katz J; Cominelli F; Regueiro M; Mansoor E
Inflamm Bowel Dis; 2023 Sep; ():. PubMed ID: 37725039
[TBL] [Abstract][Full Text] [Related]
12. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review.
Boustany A; Rahhal R; Mitri J; Onwuzo S; Abou Zeid HK; Baffy G; Martel M; Barkun AN; Asaad I
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1067-1074. PubMed ID: 37577829
[TBL] [Abstract][Full Text] [Related]
13. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
Nguyen AL; Park H; Nguyen P; Sheen E; Kim YA; Nguyen MH
Dig Dis Sci; 2019 Mar; 64(3):698-707. PubMed ID: 30327963
[TBL] [Abstract][Full Text] [Related]
14. Substance abuse and inpatient outcomes in inflammatory bowel disease hospitalizations in the United States: a propensity matched analysis.
Patel P; Ali H; Manickam S; Pamarthy R; Fatakhova K; Rajapakse R
Ann Gastroenterol; 2023; 36(1):32-38. PubMed ID: 36593809
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany.
Canbay A; Kachru N; Haas JS; Meise D; Ozbay AB; Sowa JP
Ann Transl Med; 2021 Apr; 9(8):615. PubMed ID: 33987313
[TBL] [Abstract][Full Text] [Related]
16. Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis.
Choi CJ; Weiss SH; Nasir UM; Pyrsopoulos NT
World J Hepatol; 2020 Nov; 12(11):993-1003. PubMed ID: 33312424
[TBL] [Abstract][Full Text] [Related]
17. Trends in hospital admissions and mortality among inflammatory bowel disease patients with substance use disorder: a 10-year United States nationwide analysis.
Fatakhova K; Patel P; Inayat F; Dhillon R; Ali H; Taj S; Nawaz G; Afzal A; Rehman AU; Afzal MS; Khan R; Ishtiaq R; Jones L; Rajapakse R
Proc (Bayl Univ Med Cent); 2023; 36(4):427-433. PubMed ID: 37334096
[TBL] [Abstract][Full Text] [Related]
18. P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic.
Lopes M; Shintaku D; de Oliveira AC; Beraldo R; Godoi G; Castelhano N; Vulcano D; Pereira J; de Oliveira EC; Herrerias G; Saad-Hossne R; Baima J; Barbosa W; Silva G; Sassaki L
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S11-S12. PubMed ID: 37461963
[TBL] [Abstract][Full Text] [Related]
19. Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States.
Sohail A; Ali H; Patel P; Subramanium S; Dahiya DS; Sohail AH; Gangwani MK; Satapathy SK
World J Virol; 2024 Mar; 13(1):91149. PubMed ID: 38616849
[TBL] [Abstract][Full Text] [Related]
20. Hospital costs, length of stay and prevalence of hip and knee arthroplasty in patients with inflammatory bowel disease.
Ehrenpreis ED; Zhou Y
World J Gastroenterol; 2017 Jul; 23(26):4752-4758. PubMed ID: 28765696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
